Payment overview · 2025
General Payments
$472.11
23 reported records · 13 companies
Healthcare provider profile · identity verified
Raul Couret, M.D
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · HENDERSONVILLE, TN · NPI 1306969696
Verified facts
What the public records show
CMS Open Payments records show Raul Couret, M.D received $472.11 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 14.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $68.50 | 14.5% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $67.84 | 14.4% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.36 | 11.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.30 | 10.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.28 | 7.9% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $32.48 | 6.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.77 | 6.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.38 | 5.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.22 | 4.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.12 | 4.7% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $21.98 | 4.7% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.47 | 4.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.41 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $439.63 | 21 |
| Education | $32.48 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $56.36 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.30 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.53 | 2 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $42.35 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $32.48 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.77 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.22 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.41 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 735 | 146 |
| Atorvastatin Calcium | Atorvastatin Calcium | 684 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 527 | 154 |
| Lisinopril | Lisinopril | 497 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 437 | 98 |
| Losartan Potassium | Losartan Potassium | 362 | 85 |
| Omeprazole | Omeprazole | 355 | 87 |
| Metformin Hcl | Metformin Hcl | 348 | 82 |
| Furosemide | Furosemide | 335 | 60 |
| Potassium Chloride | Potassium Chloride | 328 | 58 |
| Escitalopram Oxalate | Escitalopram Oxalate | 312 | 34 |
| Donepezil Hcl | Donepezil Hcl | 295 | 27 |
| Metoprolol Tartrate | Metoprolol Tartrate | 287 | 58 |
| Trazodone Hcl | Trazodone Hcl | 284 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 270 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 233 | 57 |
| Tamsulosin Hcl | Tamsulosin Hcl | 232 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 46 |
| Buspirone Hcl | Buspirone Hcl | 212 | 42 |
| Simvastatin | Simvastatin | 211 | 55 |
| Allopurinol | Allopurinol | 199 | 35 |
| Myrbetriq | Mirabegron | 195 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 46 |
| Metformin Hcl Er | Metformin Hcl | 185 | 44 |
| Gabapentin | Gabapentin | 184 | 54 |
| Sertraline Hcl | Sertraline Hcl | 179 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 178 | 46 |
| Clopidogrel | Clopidogrel Bisulfate | 175 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 52 |
| Eliquis | Apixaban | 164 | 25 |
| Montelukast Sodium | Montelukast Sodium | 148 | 37 |
| Bupropion Xl | Bupropion Hcl | 144 | 36 |
| Carvedilol | Carvedilol | 138 | 32 |
| Hydrocortisone | Hydrocortisone | 125 | suppressed |
| Mirtazapine | Mirtazapine | 123 | 29 |
| Ropinirole Hcl | Ropinirole Hcl | 116 | 19 |
| Meloxicam | Meloxicam | 111 | 25 |
| Ezetimibe | Ezetimibe | 107 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 23 |
| Xarelto | Rivaroxaban | 93 | 12 |
| Memantine Hcl | Memantine Hcl | 92 | 12 |
| Synthroid | Levothyroxine Sodium | 92 | 24 |
| Tradjenta | Linagliptin | 92 | suppressed |
| Glimepiride | Glimepiride | 89 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 18 |
| Ozempic | Semaglutide | 82 | 21 |
| Finasteride | Finasteride | 79 | 15 |
| Atenolol | Atenolol | 75 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 73 | suppressed |
| Alprazolam | Alprazolam | 69 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 15 |
| Lorazepam | Lorazepam | 67 | 18 |
| Alendronate Sodium | Alendronate Sodium | 64 | 16 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 62 | 62 |
| Jardiance | Empagliflozin | 62 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 61 | 33 |
| Ramipril | Ramipril | 61 | 16 |
| Farxiga | Dapagliflozin Propanediol | 60 | 11 |
| Prednisone | Prednisone | 60 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | suppressed |
| Celecoxib | Celecoxib | 58 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 58 | 35 |
| Famotidine | Famotidine | 55 | 11 |
| Clonidine Hcl | Clonidine Hcl | 54 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 54 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 18 |
| Lovastatin | Lovastatin | 50 | 14 |
| Azelastine Hcl | Azelastine Hcl | 46 | 13 |
| Chlorthalidone | Chlorthalidone | 45 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 44 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 40 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 11 |
| Bumetanide | Bumetanide | 38 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 38 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 11 |
| Irbesartan | Irbesartan | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Valsartan | Valsartan | 35 | 12 |
| Baclofen | Baclofen | 34 | suppressed |
| Calcitriol | Calcitriol | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | 12 |
| Novolog Flexpen | Insulin Aspart | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Nyamyc | Nystatin | 28 | suppressed |
| Rybelsus | Semaglutide | 28 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Cephalexin | Cephalexin | 27 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 20 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 22 |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Cilostazol | Cilostazol | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 14 |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nystatin | Nystatin | 18 | 12 |
| Repatha Sureclick | Evolocumab | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Gemtesa | Vibegron | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $472.11 · 23 records | ABBVIE INC. | AURYON LASER SYSTEM 100-120 VAC, Arikayce, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, Kerendia, Korlym, LEQVIO, Ozempic, REXULTI, The Cologuard Plus Collection Kit, VIBERZI, VOQUEZNA, WaveWriter Alpha Prime 16, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error